Edition:
United Kingdom

Claris Lifesciences Ltd (CLAI.BO)

CLAI.BO on Bombay Stock Exchange

348.65INR
10:09am GMT
Change (% chg)

Rs-2.30 (-0.66%)
Prev Close
Rs350.95
Open
Rs350.10
Day's High
Rs350.90
Day's Low
Rs346.00
Volume
49,148
Avg. Vol
161,090
52-wk High
Rs430.10
52-wk Low
Rs291.00

Select another date:

Wed, Dec 6 2017

BRIEF-Claris Lifesciences Considers Voluntary Delisting Of Shares

* SAYS CONSIDERED VOLUNTARY DELISTING OF SHARES OF CO FROM BSE LTD

BRIEF-India's Claris Lifesciences Sept-qtr consol profit surges

* Sept quarter consol profit 18.40 billion rupees versus profit of 323.9 million rupees last year

BRIEF-RBI hikes foreign investment limit in Claris Lifesciences to 49 pct

* Investment limit in Claris Lifesciences Ltd by FII/FPI raised to 49 percent and increase in NRI limit from 10 to 24 per cent Source text: http://bit.ly/2goNzjF Further company coverage:

BRIEF-Claris Lifesciences completes stake sale in JV to Otsuka

* Completes sale of its stake in JV to Otsuka Pharmaceutical India Source text: (http://bit.ly/2xh4cE9) Further company coverage:

BRIEF-Claris Lifesciences gets shareholders' nod to raise FII/FPI shareholding limits in co

* Gets shareholders' nod to raise FII/FPI shareholding limits in co Source text: http://bit.ly/2hhdhD2 Further company coverage:

BRIEF-India's Claris Lifesciences June-qtr consol profit down 13 pct

* June quarter consol profit 192.1 million rupees versus profit of 220 million rupees last year

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

Select another date: